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 Abstract  
Background: Depression is a common psychiatric problem following traumatic brain injury (TBI) with 
reported prevalence rates of 30-77% in the first year post-TBI. Given the negative influence of post-TBI 
depression on cognition, interpersonal, social, physical and occupational functioning; early initiation of 
pharmacotherapy to prevent post-TBI depression has been considered.  This systematic review will 
synthesize the available evidence from published studies on the effectiveness and harms of 
pharmacotherapy for the secondary prevention of post-TBI depression. 
Method: Studies published prior to October 2018 were eligible for inclusion. Six databases were searched, 
with additional searching of key additional documents. Studies meeting inclusion criteria were evaluated 
for methodological quality. 
Results: Six articles addressing five studies met inclusion criteria.  Study designs included three 
randomized controlled trials (RCT), two retrospective cohorts and one case-control.  Prophylactic 
pharmacotherapy included antidepressants, beta-blockers and statins. In one RCT, the number-needed-
to-treat with sertraline to prevent one case of depression post-TBI at 24 weeks was 5.9 (95%CI: 3.1-71.1). 
In a second RCT affected by significant attrition, sertraline had no effect.  Prescribing beta-blockers prior 
to TBI reduced the depression risk regardless of the specific brain trauma.  TBI patients with pre-existing 
hyperlipidemia not treated with statins had an increased depression risk compared to those without 
hyperlipidemia. 
Conclusion: Overall this systematic review yielded mixed evidence of prophylactic efficacy and insufficient 
evidence of harm. In the absence of tolerability data, existing data are insufficient to recommend 
sertraline prophylaxis.  Optimal timing and treatment duration with identification of patients most likely 
to benefit from prophylaxis require further consideration. Dedicated prospective studies assessing the 
effects of beta-blockers and statins on post-TBI depression are required. 
 Keywords 




Depression is one of the most common and disabling psychiatric complications that occurs following 
traumatic brain injury (TBI) 1,2 with studies reporting between 30% and 77% of individuals with TBI 
develop depression in the first twelve months post injury depending on the study design, irrespective of 
severity. 2-4 Rates of depression in persons with TBI are up to 7.9 times higher than rates reported in the 
general population.5  Depressive symptoms may include; sadness, irritability; fatigue; sleep disturbances; 
detachment from social activities, difficulties with concentration and memory difficulties. 6,7   
Development of depressive symptoms post-TBI is associated with adverse outcomes that hamper 
recovery including increased reporting of post-concussive symptoms 8, poorer cognitive functioning 9, 
greater physical disability, impaired participation in activities of daily living, poor adherence with 
treatment plans 10, increased health service utilization, higher healthcare costs as well as poorer 
psychosocial outcomes. 11-13 Depression can undermine the survivor’s capacity for social independence, 
employment, education and community integration 14,15.  Close relationships are at risk of breaking down 
and adding to the psychological burden felt by the survivor and their carers.16 Emotional disturbances 
along with neurobehavioural difficulties impair quality of life the most for TBI survivors 17,18.  Long term 
disability is considerable and the risk of suicide is 2.7-4.1 times greater in those with TBI and depression 
than the general population. 19-20 This highlights the need to address depression post-TBI. 
There is substantial heterogeneity associated with TBI and while not all patients with TBI develop 
depression, studies have shown that some survivors become depressed early, others become depressed 
in the post-acute stage and others have sub-threshold depressive symptoms that can lead to later 
depression. 21 Contributory factors to the onset and course of post-TBI depression include the extent of 
social support and post-acute services, preinjury mental health disorders, injury related changes and 
posttraumatic adaptive issues. Gender, age and level of education are important in some studies but not 
in others. 2 Once depression becomes established it likely becomes more difficult to treat and many 
individuals post-TBI require medications over extended periods for depression. 21,22  
 Given the high prevalence of depression post-TBI, consideration of a preventative approach may be an 
option and indeed a desirable goal for clinicians, patients and carers. Secondary prevention aims to 
reduce the impact of a disease or injury that has already occurred. In the case of TBI, this is done by 
treating the TBI and associated symptoms like depression as early as possible to halt or reduce the 
likelihood of symptoms becoming chronic while at the same time implementing programs to return 
individuals to optimal health and function to prevent long-term problems.  
Currently, the management of depressive symptoms post-TBI involves a multimodal and multidisciplinary 
approach incorporating social, psychotherapeutic and medical interventions 23,24. Despite their potential 
for a lesser tolerability burden in this vulnerable population, unfortunately neither psychotherapeutic nor 
social interventions have an adequate evidence base to routinely support their use at this time. 25 The aim 
of pharmacotherapy is to provide targeted treatment for emotional disturbances on an individualized 
basis while managing the adverse effects of medications.  A preventative approach to depression post-TBI 
would require supportive data indicating efficacy in prevention that is clinically meaningful in size. 
Further, preventative interventions would require a highly favourable risk benefit balance as some 
patients will inevitably be exposed to an intervention they do not need. This may appear less of a concern 
with a low risk intervention such as planned social interaction or even specific psychotherapeutic activity 
to facilitate adjustment. The utilisation of antidepressants is associated with more significant risks and 
would thus require significant evidence of benefit as well as clear information on those risks before 
clinicians and patients could feel comfortable proceeding. 
Previous studies have examined the efficacy of prophylactic treatment with antidepressant medications in 
other impaired cohorts at elevated risk of depression including persons undergoing open heart surgery,26 
those receiving anti-viral treatment for chronic hepatitis C,27 and individuals being treated for stroke, 28 
head and neck cancer,29 and acute coronary syndrome. 30 Overall findings support the use of medication 
for secondary prevention of depression. The findings of the systematic review on stroke are particularly 
 relevant to the TBI population. Eight studies were included; pooled analyses indicated reduced odds of 
post stroke depression associated with pharmacologic treatment (odds ratio: 0.34, 95% CI 0.22-0.53). 
Given the debilitating nature of depression and the major impacts it can have on functioning and quality 
of life, consideration of the safety and effectiveness of prophylactic pharmacotherapy to reduce the risk 
of depression in an “at risk” population cohort is warranted.  
 
As far as we can determine, prophylactic pharmacological management to reduce the risk of depression 
post-TBI has not been considered in clinical guidelines for TBI.  Prior systematic reviews and meta-
analyses of the pharmacological management of symptomatic depression post-TBI report that 
pharmacotherapy post-TBI may be associated with a reduction in depressive symptoms; 23,31,32 no 
systematic reviews could be found that have identified and synthesized the evidence for prophylactic 
pharmacological management of depression post-TBI.   
This review forms part of a larger project to synthesize the evidence for the pharmacological management 
of neurobehavioural symptoms post-TBI as a prelude to the development of a clinical guideline for the 
pharmacological management of neurobehavioural symptoms following TBI. While the prophylactic use 
of pharmacotherapy as maintenance treatment following an initial depressive episode is common,33,34 this 
is not the focus of this review. 
The objective of this systematic review is to identify and synthesize the current evidence on the 
effectiveness and harms of prophylactic pharmacological treatment for the secondary prevention of 
depressive symptoms post-TBI. 
  
 MATERIALS and METHODS 
Inclusion and exclusion criteria  
Articles were selected for inclusion in the systematic review according to the following criteria.  
Types of Participants 
This systematic review includes studies of individuals who have sustained a TBI and were asymptomatic 
for depression at the time of study recruitment. For a study to be included in the review, depressive 
symptoms could be determined either by self-report or using a standardized diagnostic interview or 
validated assessment tool (e.g. Diagnostic and Statistical Manual of Mental Disorders criteria (DSM) or 
MINI  International Neuropsychiatric Interview).  
Traumatic brain injury is defined as an alteration in brain function, or other evidence of brain pathology, 
caused by an external force. Participants must have definite medical evidence of TBI. For the purpose of 
this review, this means that TBI had been documented in medical records or other health-medical reports 
sighted by the research team associated with the published article. These records had to provide 
unequivocal evidence of injury. Examples of unequivocal evidence include findings from brain imaging, 
Glasgow Coma Scale (GCS) score, post traumatic amnesia (PTA), loss of consciousness. Any reported 
period of PTA and reporting of GCS score (3-15) was taken to indicate the presence of TBI. As risk of 
depression increases over time post-TBI, only individuals in the early stages of recovery with a clinical 
assessment that they do not currently meet the criteria for a depressive disorder were included.  As there 
is no universal time frame for ‘early recovery’, for the purpose of the review, early recovery was  defined 
as within eight weeks post-injury. 
This review included: 
 Studies including persons 16 years and over, both males and females, who had sustained a TBI of 
any severity.   
 Studies where >= 80% of the baseline population are 16 years and older.  
  Studies were included regardless of injury mechanism with both penetrating and non-penetrating 
injuries included.   
 Studies of acquired brain injury populations if data for TBI participants are reported separately.  
This review excluded:  
 Studies including self-reported TBI in the absence of other medical evidence regarding the head 
injury. 
 Studies relying on self-report of depressive symptoms in the absence of a standardized diagnostic 
interview, validated scale or DSM criteria. 
 Studies reporting on clusters of individuals rather than individuals themselves e.g. clinic 
attendees, families, people living in a defined geographical area. 
Types of Intervention(s) 
The focus of this review was on pharmacotherapeutic interventions. No restriction on dose, duration, 
frequency, timing of delivery, or combination of drug therapy was made. Pharmacotherapy had to be 
prescribed by a health provider. Studies of mixed interventions (e.g., pharmacotherapy and psychological 
therapy) were included only if the data for the pharmacological intervention was reported separately. 
Studies of complementary medicines and over the counter medicine were excluded unless these were 
part of the intervention, as a co-intervention to pharmacotherapy. 
Types of Comparator(s) 
This review included studies that compared the pharmacological intervention with all types of 
comparators. There were no restrictions on the type of comparator; placebo (dummy or active), 
supportive, standard care or a non- pharmacological intervention. Studies comparing drugs within a 
pharmacological class were eligible for inclusion. 
Types of Outcomes 
The primary outcomes of interest for the review were: 
  Prescription of antidepressant therapy in the first 12 months post-TBI 
 Incidence of new onset depressive disorder in the first 12 months post-TBI 
 Time to onset of a depressive disorder 
The secondary outcomes of interest were: 
 Harms including adverse effects resulting from pharmacotherapy and study dropouts. 
o Adverse effects general and specific (qualitatively documented or documented using 
Medical Dictionary for Regulatory Activities (MEDRA), WHO Adverse Reaction 
Terminology (WHO-ART) or other classification systems) associated with 
pharmacotherapy. The need for medication to manage adverse effects as reported. 
o Study dropout:  Loss to follow-up and leaving the study early due to adverse events, 
inefficacy of treatment, death, any reason 
Types of studies 
This review considered the following study types 
 Randomised controlled trials; Controlled non-randomised clinical trials; Quasi-randomised 
controlled trials including, for example but not limited to controlled before and after studies, 
interrupted time series with a control group, interrupted time series without a parallel concurrent 
control group; analytical observational studies (including cohort and case–control studies) and 
single arm studies.  
The following study types were excluded: editorials and opinion pieces, qualitative research, case reports, 
single case experimental designs, methodological papers, secondary studies including narrative reviews, 
systematic reviews and meta-analyses. 
Search Strategy 
The literature search was limited to the English language and human subjects. No date restriction was 
applied to the search for literature. This review was not registered on Prospero. 
 Published and unpublished studies were identified using a seven step approach. Initially, the Cochrane 
Library and Pubmed were searched to identify key words used in titles and abstracts and in the search 
strategies of relevant published systematic reviews. Second, a more extensive search of international 
electronic bibliographic databases was undertaken to further identify articles. The following databases 
were searched with no date limitation: MEDLINE, OVID SP interface; Pubmed excluding MEDLINE; CINAHL: 
Cumulative Index to Nursing and Allied Health Literature; EMBASE: Excerpta Medica Database excluding 
MEDLINE, OVID SP interface; PsycINFO, OVID SP interface;  Cochrane Library: CENTRAL.  
An information specialist with extensive experience in conducting systematic reviews developed and 
executed the search strategy for each database. Third, we conducted backwards citation searching of all 
reference lists of retrieved articles were reviewed to identify research articles not located through other 
search strategies. Fourth, electronic searching of the following online journals: Brain Injury, 
Neuropsychology, Journal of Neurotrauma and Journal of Head Trauma Rehabilitation were carried out.  
Fifth, the clinical trial registries: International Clinical Trials Registry Platform Search Portal and 
ClinicalTrials.gov were searched to identify ongoing studies. Sixth, we searched Research Gate and the 
international drug regulators Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) to identify unpublished studies. We also consulted international experts in the study of TBI for 
relevant citations. Finally, to ensure as complete a search as possible, we supplemented a formal 
database searches by seeking additional citations from Google Scholar.  
 
Search terms were mapped to Medical Subject Headings (MeSH) terms or subject headings and linked 
together using Boolean operators. The search strategies for the other databases was based on the 
PubMed strategy and modified in accordance with the specific requirements for the other databases.  
This systematic review is part of a large project that will review and update the current evidence on a 
range of neurobehavioural symptoms as the first stage in the development of a clinical guideline on 
pharmacotherapy for the management of neurobehavioural symptoms in adults post-TBI in Australia. The 
 search strategy was developed based on the PICO (Population, Intervention, Comparator, Outcome) 
elements of relevance to this review (P=TBI, I=pharmacotherapy). The full search strategy for Ovid 
Medline is provided in Appendix 1.  
Study Selection 
Following the search, all identified citations were collated, uploaded into Endnote X8 and duplicates 
removed. Titles and abstracts were screened by pairs of independent reviewers (FC/LP and AH/RB) for 
assessment against the inclusion and exclusion criteria for the review. Disagreements were resolved 
through consensus.  
Studies that potentially met the inclusion criteria at the title/abstract stage were retrieved in full and 
independently assessed against the inclusion criteria by two review team members (FC/LP and AH/RB).  
Disagreements over eligibility were resolved through discussion with a third reviewer (MH).  
Reporting of the review adhered to the PRISMA guidelines. The results of the search are presented in a 
PRISMA flow diagram (Figure 1). Full text studies that did not meet the inclusion criteria and reasons for 
exclusion are provided in the PRISMA diagram.   
Quality Assessment  
Methodological quality was reported using the Cochrane Risk of Bias and Joanna Briggs Institute (JBI) 
cohort and case control critical appraisal instruments. Independent critical appraisal was conducted by 
two reviewers (FC/HZ); disagreements were resolved through discussion with a third reviewer (MH). No 
studies were excluded based on methodological quality; however the results were taken into account 
when drawing conclusions about the study findings.  
The Cochrane Risk of Bias for clinical trials 41  assesses risk of bias across seven domains: sequence 
generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and 
personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data 
(attrition bias), selective outcome reporting (reporting bias) and other potential sources of bias. The JBI 
 critical appraisal tools assess methodological quality of case control studies and cohort studies using 10 
item and 11 item tools respectively. The questions that comprise each tool are included in Appendix 2. 
Data Extraction 
Where available, we extracted data from each of the included studies on design, analysis and results. The 
data were extracted using a customized data extraction tool piloted on two articles that do not form part 
of the review. Minor changes were made following the pilot testing.  
 
After full review, the following data were extracted as they appeared in the original publication: country 
where study was carried out and setting, study design, baseline sample size, main inclusion and exclusion 
criteria, outcomes, outcome measures and timing of measurement, participant demographics and 
baseline characteristics, type of analysis, statistical procedures, study completion rates, compliance rates 
and extent of missing data, main results, treatment harms and adverse events.  The following data were 
collected where available for the study population, depression diagnosis and pharmacotherapy 
intervention; TBI study population (nature of injury, injury severity, assessment scales, other injuries, time 
post-injury); depression diagnosis - assessment scales, severity, other symptoms, timing of onset, 
diagnostic criteria; pharmacotherapy intervention/exposure and control conditions if used including drug 
name and drug class, treatment dose, frequency and duration. 
  
 RESULTS 
Literature search  
The identification of literature and the screening process was completed for the broader study 
encompassing a range of neurobehavioural symptoms post-TBI, with selection of studies specifically 
related to prophylactic treatment to reduce the risk of depressive symptoms made after the screening 
was completed. The initial literature search identified 9468 articles from bibliographic databases and 445 
from additional search sources. Following the search, all identified citations were uploaded into 
Endnote and 2030 duplicates removed, leaving 7883 to be screened for inclusion. After screening of title 
and abstract, a further 7572 articles were removed leaving 311 articles to be reviewed as full-text in order 
to determine whether they met study inclusion criteria. After full review, 239 further articles were 
excluded leaving 72 articles to be screened. Of these, 66 articles were deemed to not meet the inclusion 
criteria for this review with three articles eligible for this review. The percentage agreement between the 
two independent authors who completed the full-text screen was 83.3%. The search was rerun in 
November 2017 and identified a further three articles bringing the total number of articles eligible for 
inclusion in this review to six. These six articles reported on five unique studies.  The literature search was 
rerun in October 2018 with no additional articles identified. The screening process and reasons for 
exclusion at full-text stage are documented in Figure 1. 
Six articles representing five unique studies are included in the evidence tables on prophylaxis for the 
prevention of depression post-TBI. Three studies were randomized controlled trials (RCTs), two studies 
were retrospective cohorts based on trauma registry participants and the final study was a case control 
study using the Taiwan National Health Insurance Database. Two of the RCTs reported on the same study.  
Of the five unique studies included in this review, two were conducted in the USA 35,36, two in Sweden 37,38 
and one in Taiwan 39.  
Sertraline was the pharmacotherapy evaluated in the three randomized controlled trials 35,36.  Two 
retrospective cohort studies examined the impact of beta-blockers given prior to sustaining a TBI 37,38 and 
 the final study examined the risk of new onset depression in TBI patients with hyperlipidemia who were 
treated with statin medications 39.  
The Jorge et al, 36 and Novack et al, 35 sertraline studies at baseline included a total of 195 individuals; the 
studies of beta-blockers included 148 matched pairs; and the sample for the statin medication study 
involved 3792 individuals. Consistent with the TBI population, there were more males than females in all 
of the included studies. For four of the five unique studies, the hospital was the setting. Only one study 
considered treatment harms 36. Outcomes were measured up to 12 months except for one study by Ahl 
that measured outcomes to five years. 
Sertraline studies 
The sertraline RCT studies are outlined in Table 1. The Jorge, 2016 RCT investigated the efficacy of 
sertraline versus placebo in preventing depressive episodes following TBI 36.  Patients were randomised to 
either sertraline 100mg daily or placebo for 24 weeks or until the development of a mood disorder. The 
main outcome measure was time to onset of depressive disorders. The number needed to treat for 
sertraline versus placebo to prevent depression at 24 weeks was 5.9 (95%CI, 3.1-71.1; χ2 = 4.6; P = .03) in 
other words, for every 5.9 post-TBI individuals administered sertraline, one would avoid being 
subsequently diagnosed with a depressive disorder.  While these outcomes are not the focus of this 
review, the authors noted that there was no difference in psychological scale scores (Apathy Evaluation 
Scale, Disability Rating Scale, Mania Rating Scale, Hamilton Anxiety and Depression Rating Scales, Clinician 
Administered PTSD Scale, Modified Overt Aggression Scale, Alcohol Use Disorders Identification Test) 
between the sertraline and placebo group at 24 weeks 36.  The authors recognised the limitations of this 
study, in particular the small sample size and the follow-up period being restricted to six months.  
The Novack et al, 2009 RCT examined the effectiveness of sertraline administered in the first three 
months after moderate to severe TBI in reducing the incidence of depression 35. Patients were given 
either sertraline 50mg once daily or placebo for three months. The primary outcome was the 
development of depressive symptoms and this was measured using the Hamilton Depression Rating Scale 
 and the Neurobehavioural Functioning Inventory- Depression Scale.  During the 90 day intervention there 
was no cases of depression identified in the sertraline group whereas in the placebo group three cases 
were detected (χ2 =3.03, p=0.08).  For the remainder of the 1-year follow-up period, four cases (8.2%) of 
depression were identified in the treatment group, and seven in the placebo group (14%)  (χ2=0.133, 
p=0.72)35. The results do not support the early prescription of sertraline post-TBI to prevent depressive 
symptoms.  Limitations of this study were the high dropout rate of 19/49 participants in the treatment 
group, 10/50 in the placebo group, small sample size and the low dose of sertraline used in the study35.  
The Banos et al, 2010 study was based on the same group of patients utilizing the same method and 
exposure of interventions between the groups as described for the Novack study 40. The aim of this study 
was to assess whether sertraline improved cognition and behavioural outcomes.  Outcome measures 
included the Neurobehavioural Functioning Inventory (NFI), Working Memory Index, Trail Making Test, 
Wechsler Memory Scale and Symbol-Digit Modalities Test. With the exception of the NFI, these outcomes 
are not the focus of this review.  The reporting of results for the NFI depression subscale differ between 
the Novack and Banos studies. Due to the lack of information provided it is not possible to determine 
whether one was based on an intent to treat analysis and the other represented the efficacy subset. The 
study concluded that sertraline did not appear to prevent development of cognitive and behavioural 
problems post-TBI 40.  
Beta-Blocker studies 
The characteristics of the two beta-blocker retrospective cohort studies together with their findings are 
outlined in Table 2.  Both of the Ahl et al studies 37-38 were retrospective cohorts that examined the effect 
of beta-blockers on depression post-TBI 37. In the two retrospective cohort studies, 66% and 70% of the 
patients were on the lipophilic beta blocker metroprolol, twelve months prior to admission. Patient’s 
naïve to beta blockers pre-injury were allocated to the non-beta blocker group together with a minority of 
 patients exposed to beta-blockers either in a single dose or a limited (non-continuous) number of times 
during their admission. 
In the Ahl et al study published in World Surgery, the cohort comprised individuals with severe extra 
cranial injuries37.  Propensity matching was used to create pairs of individuals who had been prescribed 
beta-blockers and compare their outcomes with individuals who did not receive beta-blockers. Individuals 
with and without pre-admission b-blockers were matched 1:1 by age, gender, Glasgow Coma Scale, Injury 
Severity Score and head Abbreviated Injury Scale.  The primary outcome was the measurement of post-
traumatic depression one year after TBI.  Findings from the study were that trauma registry patients not 
on beta-blockade therapy had increased odds of depression (AOR 3.3, 95% CI 1.2–8.6, p = 0.02)37. The 
study concluded that patients on beta-blockers prior to sustaining their TBI had significantly reduced odds 
of developing depression up to one year after sustaining a severe TBI. The study did not record the 
different beta-blockers used 37.  
The second study by Ahl and colleagues looked at the administration of beta-blockers prior to severe TBI 
on the development of depression. 38 The results from this study demonstrated that more patients who 
were not on beta-blockers prior to the TBI 33% (n=26/80) developed post traumatic depression, than 
patients who were taking beta-blockers 18% (n=14/80) (p=0.04).  The study concluded that beta-blockers 
act prophylactically to lower the risk of post-traumatic depression in patients suffering from TBI.38 The 
study had several limitations, notably the retrospective cohort study design and the inability to control 
the type of beta blockers used by patients. 38  
Statin study 
The statin case-control study reported in Table 3 found that TBI patients with high cholesterol levels are 
at a greater risk of depression especially when their hyperlipidemia is not kept under control with statins.   
The Wee et al study was a matched case control study with 3 years of follow-up examining the role of 
statin medications in the management of hyperlipidaemia and the risk of developing new-onset 
 depression post-TBI.39 Using 8 years of Taiwan longitudinal health insurance data (1/2001-12/2008) -
researchers followed 3792 patients with TBI with no history of depression. Of the participants, 1,264 
showed signs of pre-existing hyperlipidemia and each of these participants were age and sex  matched to 
two others without hyperlipidemia from the overall cohort. 39 During the final three years of follow-up, 4 
percent of TBI patients with hyperlipidemia and 2.3 percent without hyperlipidemia exhibited signs of 
depression. After controlling for age, sex, income, statin use and the comorbidities of hypertension, 
cardiovascular disease or diabetes, TBI patients with hyperlipidemia were 61% more likely to develop 
depression 39. 
The study established hyperlipidemia as an independent risk factor for a new depression diagnosis up to 
three years post-TBI. There was a 1.72 fold increased incidence of depression in TBI patients with 
hyperlipidaemia than without (p=0.0056). Furthermore, TBI patients with hyperlipidaemia not treated 
with statins experienced a 1.95 fold incidence risk ratio (p=0.0017) and higher risk of post-TBI new onset 
depression (HR=1.61; 95% CI, 1.03-2.53) compared to TBI patients without hyperlipidaemia (p=0.0378).39  
Together this suggests a critical role for statins in the development of new-onset depression 39. 
Harms   
Adverse events due to treatment were only reported in one study 36 where patients were prescribed 
sertraline. One patient in both groups experienced a serious adverse event (fractured hip) which was not 
associated with the study medication. Patients who received sertraline were at a higher risk of 
experiencing dry mouth (OR=7.2; 90% CI, 1.9-27.6; p= .01) and diarrhoea (OR= 2.3; 90% CI, 1.0-5.5; p = 
.10) compared to placebo 36.  
Quality assessment  
The quality assessment rating for each of the included studies is included in Table A. Methodological 
quality assessments were independently conducted by two reviewers (HZ,FC). Risk of bias for 
experimental studies was conducted using the criteria as recommended by Cochrane Effective Practice of 
 Care (EPOC) group 41. RCTs were assessed for generation of allocation sequence, concealment of 
allocation, baseline outcome measurements, baseline characteristics, incomplete outcome data, blinding 
of outcome assessor, protection against contamination, selective outcome reporting and other risks of 
bias using the Cochrane Risk of Bias tool 41. For retrospective cohort studies the Joanna Briggs Institute 
Critical Appraisal Checklist for Cohort Studies was used (see Appendix 2).  The Kappa statistic for risk of 
bias ratings was not calculated. 
The three intervention studies included in this review varied in terms of their risk of bias. The Jorge study 
was assessed as being at low risk of bias 36, whereas for the Novack and Banos studies it was difficult to 
reach conclusions regarding  the risk of bias due to lack of data and information contained within the 
studies. The Novack and Banos study was affected by significant attrition with no explanation provided for 
the loss to follow-up 35,40. The two retrospective cohort studies by Ahl and colleagues were judged to be at 
low risk of bias with most criteria in the critical appraisal of cohort studies being met37,38. However, both 
studies used a proxy indicator of depression based on prescription of antidepressants.  The case-control 
study by Wee was judged as having a low risk of bias 39.  
 DISCUSSION 
The focus of the current systematic review was to assess the effectiveness and tolerability of using 
prophylaxis medication to prevent the onset of depression post-TBI. The studies included in the review 
examined the effects of sertraline, beta-blockers and statins on the risk of new onset depression. Despite 
the use of different study designs, overall, the results provide some early support for a prophylactic 
secondary prevention approach. 
Three articles focusing on two studies considered the effectiveness of sertraline. In the RCT by Jorge et al  
of the 94 patients in the study, the number needed to treat to prevent depression at 24 weeks post-TBI 
was 5.9 for sertraline treatment vs placebo (p=.03, 95% CI:3.1-71.1)36. In contrast, the RCT by Novack, 
Banos and colleagues did not find significant differences in rates of depressive symptoms between the 
treatment and placebo groups 35,40. The Novack/Banos study was subject to significant attrition and there 
was no attempt to address the missing data in the analysis. Comparability between the two studies is 
limited due to the use of different dosages of sertraline (50mg/day, 100mg/day). The dose (50mg/day) of 
sertraline may have been suboptimal to impact serotonin levels. Moreover the lack of effect may be due 
to a smaller sample size than intended.   
Sertraline belongs to a class of antidepressants called Selective Serotonin Reuptake Inhibitors (SSRIs) 
which prevent the uptake of serotonin by monoamine transporters in the presynaptic cleft  thereby 
increasing the availability of serotonin in the synaptic cleft. 42 Serotonin is thought to impact mood, 
arousal and working memory and therefore SSRIs are seen as suitable pharmacotherapy for post-TBI 
neurocognitive and neuropsychiatric deficits. 42  
Despite the lack of current evidence to support the use of SSRIs in a post-TBI population, in non-TBI 
populations, SSRIs have been shown to significantly improve function and depressive symptoms 
suggesting that they are both effective and well tolerated.43 As the use of SSRIs becomes more 
widespread in TBI patients, the risks associated with pharmacological treatment have become more 
 apparent 43. SSRIs are associated with lowering the seizure threshold 42 and in patients with TBI, late onset 
seizures are a recognized problem. The extent to which SSRIs treatment exacerbate risk of seizures has 
yet to be quantified. Antidepressants with strong serotonin reuptake inhibition properties can increase 
the risk for intracranial hemorrhage particularly in the first months of administration. If anticoagulants are 
also prescribed, the impact may be greater. The risk of bleeding stems from inhibition of serotonin 
reuptake in platelets 44.   Other notable adverse effects of SSRIs include; serotonin syndrome, emergence 
of mania, hyponatraemia, impotence/sexual dysfunction, interactions with anticonvulsants and 
gastrointestinal effects 42-43.  In the RCT by Jorge et al, adverse events were recorded 36. Notably, there 
was an increased odds of diarrhoea and dry mouth in the arm receiving sertraline. While the review by 
Jones et al noted that SSRIs appeared to be well tolerated post-TBI in the Jorge et al study, it does not 
discount the possibility of more serious side effects in a larger sample recruited from more than one 
location or country 45.  
The studies by Ahl and Wee used trauma registries 37-39 and administrative claims databases39 to 
retrospectively examine the effectiveness of beta-blockers and statins on new onset depression post-TBI. 
It is important to emphasize that these patients were not prescribed beta-blockers or statins because they 
had a TBI and physicians were concerned about depression. The registry and health insurance databases 
were not set up to explicitly assess the relationship (if any) between these pharmacotherapies and new 
onset depression. In this regard, these studies37-39 differ from the RCTs that focused on 39 prescription of 
sertraline. It is also one reason why there is no information on harms and adverse events in these studies. 
In terms of effectiveness of the pharmacotherapy and potential application as a prophylactic treatment, 
the lack of information on harms is a significant concern. While the three studies show promise with 
respect to the measured outcomes, before any consideration of the clinical use post-TBI of these 
pharmacotherapies, further studies in large well conducted randomized controlled trials involving post-
TBI patients are needed to confirm the benefits and harms of beta-blockers and statins.  
 Beta Blockers  
Beta blockers have varying impacts on glucose control, depression and lipid dysfunction. The mechanism 
of action of beta-blockers on behavioural disorders remains unclear but it is proposed they reduce 
hyperadrenergic activity.46 In patients with TBI there can be an imbalance in the autonomic nervous 
system which leads to increased sympathetic activity termed as Paroxysmal Sympathetic Hyperactivity 
(PSH).47 PSH is thought to be one potential mechanism of agitation post-TBI. Beta-blockers are 
hypothesized to protect against social anxiety and have been used to treat and reduce the intensity and 
frequency of neurobehavioral symptoms such as agitation or aggression in the subacute and chronic 
phases of TBI. 48  
 
The benefit and safety of beta-blockers post-TBI, as well as their differential effects and interactions are 
uncertain.  There is a lack of research on the long-term effects on functional recovery and cognitive 
capacities are not well studied. Attention needs to be paid to the safety of beta-blockers in TBI. The one 
RCT study that did investigate clinically significant adverse effects of beta-blockers including hypotension, 
bradycardia, bronchospasm and congestive heart failure in TBI patients compared to placebo revealed no 
increase adverse events in the beta-blocker group 49.   
 
A proxy outcome for depression –antidepressant therapy within one year post discharge was used in the 
two studies by Ahl and colleagues 37,38. This may overestimate the odds of a depressive disorder diagnosis 
as beta-blockers are sometimes prescribed off label to manage an individual’s physical reactions to a 
range of anxiety disorders including social anxiety disorder and performance anxiety.  
Statins  
The included study by Wee et al, 2016 found that TBI patients with preexisting hyperlipidemia that was  
not treated with statins had a greater risk of new-onset depression than TBI patients without 
hyperlipidemia.39  Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors 
 that influence multiple mechanisms of acute and secondary neuronal injury. Although the beneficial 
effects of statins have been ascribed to their lipid lowering properties there is now evidence that statins 
have additional neuroprotective properties that may promote the timely resolution of the inflammatory 
response, preventing persistence of inflammation and resultant pathology post-TBI. 50  Statins have mixed 
effects as neuroprotection agents with some studies reporting beneficial effects of statins with respect to 
neuroprotection while other studies do not. 51,52 While the study by Wee provides support for an effect of 
statins post-TBI, the precise effect with respect to depression remains to be established.  
Statins have been widely used and their adverse effect profile is well documented with few complications. 
However, statins can cause rhabdomyolysis 53, and it is not known whether patient’s post-TBI, or those 
with hypoperfusion are more prone to this problem. Statins are also known to affect the coagulation and 
fibrinolytic systems, despite this a clinically significant effect on coagulopathy in TBI patients not having 
been reported. 54 Moreover, in 2012 the U.S Food and Administration issued a statement on cognitive 
impairment as a potential adverse effect of statins, with myopathy being the most well-characterized 
adverse sequalae. 55 The use of statins in a TBI population could present risks if abrupt discontinuation is 
required, for example because of an adverse event, as this may exacerbate neuroinflammation that is 
occurring because of the TBI. 56-57  
 
Practical concerns 
Prescriptions drugs like sertraline are approved by regulators like the Therapeutic Good Administration 
(TGA) for a particular indication. Off-label prescribing happens when a drug is prescribed for an indication, 
route of administration or patient group that is not included in the approved product information 
document for that drug. It means that the regulator has not approved the indication, route of 
administration or patient group.  The prescription of sertraline for the secondary prevention of 
depression in a person post-TBI is an example of off label prescribing 
 While there are no legal barriers to prescribing off-label, the prescriber must be able to defend their 
prescription for an indication not listed in the product information.  The grounds for off-label prescribing 
are likely to be open to more scrutiny should a serious adverse event related to the medication occur.  
One of the risks with using medicines off-label is that the quality of evidence to support such use may be 
lower than for approved indications. If the medicine is used for an off-label patient population such as 
those post-TBI, the risks and side effects may be unclear.  Moreover, the extent to which patients will 
benefit from using the medicine might be unknown as the effectiveness of a medicine used for an off-
label indication may not have been comprehensively assessed in clinical trials. In the case of the current 
review, only one of the studies on sertraline reported on the harms. The RCT was relatively small with 
recruitment being restricted to a single site in the USA. 
For the patient, the cost of using medicines off-label may be prohibitive. Medicines prescribed off-label 
are not eligible to be subsidized on the Pharmaceutical Benefits Scheme in Australia, meaning the patient 
has to pay the full cost. In the case of sertraline, betablockers and statins which are now all off patent, the 
costs are not expensive.  If prescribed medicines are subject to reimbursement from other sources, for 
example, insurance providers, off-label prescribing may have implications for reimbursement.  
Clinical concerns 
The clinical utilization of preventative antidepressant therapy in high risk situations such as post-TBI 
remains controversial. The majority of existing evidence on the use of antidepressants in the treatment of 
major depression in a general population lies in either acute episode treatment or prophylaxis in 
individuals with an established history of depression.  This evidence alone cannot be taken to indicate 
antidepressants will be similarly efficacious in someone with no history of depression but significant risk 
factors for depression. It is also clear that not all or even perhaps the majority of individual’s post-TBI will 
experience major depression. This suggests that most individuals given prophylactic interventions in this 
 case antidepressants will not require them. If this is the case, any intervention must have a very low risk 
of potential harm to justify its use.  Finally, the clinical utility of these findings is affected by the variability 
across the six studies in the end outcome of depression. 
Ethical concerns 
It is appropriate to consider the application of the ethical principles of beneficence and nonmaleficence, 
to the prophylactic secondary prevention approach to reduce the risk of depression in individual’s post-
TBI including the possibility of prescribing to individuals who may never get depression. Physicians need 
to ensure that the individual risk of depression in patient’s post-TBI is properly and progressively assessed 
and managed along the post-TBI continuum of care. The outcome of an assessment, together with shared 
decision making with the patient might result in prescribing pharmacotherapy. Alleviating the risk of 
depression post-TBI needs to be balanced with the equally important responsibility of not exposing 
individuals to unnecessary harms associated with medication.  
The ethical principle of beneficence specifies that a physician must provide a net benefit to the patient.  
Given the lack of research on depression post-TBI; even with clinical experience, empathy and an open 
mind, it is not simple to estimate the benefits that a post-TBI patient will obtain from pharmacotherapy. 
The principle of nonmaleficence guides physicians to avoid or minimize harm or the risk of harm, the 
physician must consider the harms and risks of adverse effects associated with prescribing medication to 
the patient.  
Strengths and Limitations 
This systematic review has a number of limitations. Only a small number of studies were identified and 
given this meta-analysis was not appropriate. Moreover, the studies considered three different 
medications and there was insufficient detail available on the timing of the pharmacologic agent delivery. 
The studies of beta-blockers and statins didn’t differentiate the drugs further, so we are not able to 
 attribute an effect to a particular drug. Given the retrospective nature of some of the studies, 
pharmacovigilance data on harms and adverse events was not available. Moreover, the findings from the 
statins and beta-blockers studies need to be interpreted with caution as a direct causal link cannot be 
established given that these studies were retrospective.  It is possible that we have missed relevant peer 
reviewed articles. We think the likelihood of this is small given the involvement of an information 
specialist in the design of the search, the range of databases searched, reference lists consulted and 
search of Google scholar and grey literature.  
Notwithstanding this, the strengths of the review include the systematic identification of relevant studies 
using a specified search strategy developed by an information specialist that included a search of clinical 
trials sites and a critical appraisal of the reports quality. Moreover, no date restriction was applied, all 
studies were assessed for methodological quality and we followed the PRISMA reporting guidelines. 58 The 
review brings together five independent studies of prophylactic treatment to prevent the onset of post-
TBI depression. By doing so it helps clinicians to better understand the clinical course of depression post-
TBI and may offer guidance in the personalization of treatments in clinical practice.  
  
 CONCLUSION 
This systematic review has identified and synthesized the evidence on the prophylactic use of medication 
to prevent the onset of depression post-TBI.  The review included six articles reporting on five studies 
involving sertraline, beta-blockers and statins. Overall, the review identified mixed evidence of 
prophylactic efficacy for the three drug classes and insufficient evidence concerning harm. While we hope 
this review will serve to stimulate further study on pharmacologic prophylaxis in this population, concerns 
over the quality of evidence, cost of medications, off-label prescribing, lack of data on safety together 
with the clinical and ethical concerns over potentially prescribing medication to individual’s post-TBI who 
may never get depression limit any recommendations for clinical practice. Moreover, given the range of 
severity for both depression and TBI, a prophylactic pharmacological intervention may not meet the 
needs of all patients at risk of developing depression post-TBI  
In the age of genomics and personalized medicine, finding biomarkers to identify individuals at greater 
risk of depression may focus prophylactic secondary prevention to those who are most at risk of 
developing depression post TBI.  Until then, further research in large post-TBI cohorts using a range of 
study designs that collect data on risks and harms is needed. A clear definition of depression, depression 
severity and reporting of the specific pharmacological drug including the dose, frequency and time to drug 
initiation would be informative.  
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 APPENDIX 1 
MEDLINE search strategy 
1. Exp Brain Hemorrhage, Traumatic/ OR Brain Injuries/ OR Brain Injury, Chronic/ OR Cerebral 
Hemorrhage, Traumatic/ OR Cerebrovascular Trauma/ OR Craniocerebral Trauma/ OR Diffuse Axonal 
Injury/ OR Exp Head Injuries, Closed/ OR Head Injuries, Penetrating/ OR Exp Intracranial Hemorrhage, 
Traumatic/ OR Exp Pneumocephalus/ OR (((Brain OR Cerebr$ OR Crani$ OR Crushing Skull OR Diffuse 
Axonal OR Head OR Hemisphere?) adj1 (Injur$ OR Trauma$)) OR ((Cerebr$ OR Crani$ OR Head) adj 
(Lesion? OR Wound?)) OR ((Posttraumatic OR Traumatic) adj Encephalopath$) OR (Traumatic adj 
(Brain OR Cerebr$)) OR Concuss$ OR DAI OR DAIs OR Pneumocephalus OR TBI OR TBIs).ti,ab. 
2. "Anti-Anxiety Agents"/ OR "Anticonvulsants"/ OR "Antidepressive Agents"/ OR "Antipsychotic 
Agents"/ OR "Benzodiazepines"/ OR "Adrenergic Beta-Antagonists"/ OR Alprazolam/ OR 
Amitriptyline/ OR Amoxapine/ OR Aripiprazole/ OR Atenolol/ OR Atomoxetine Hydrochloride/ OR 
Benztropine/ OR Bromazepam/ OR Bupropion/ OR Buspirone/ OR Carbamazepine/ OR 
Chlordiazepoxide/ OR Chlorpromazine/ OR Citalopram/ OR Clomipramine/ OR Clonazepam/ OR 
Clopenthixol/ OR Clorazepate Dipotassium/ OR Clozapine/ OR Desipramine/ OR Desvenlafaxine 
Succinate/ OR Dextroamphetamine/ OR Diazepam/ OR Valproic Acid/ OR Domperidone/ OR 
Dothiepin/ OR Doxepin/ OR Droperidol/ OR Duloxetine Hydrochloride/ OR Estazolam/ OR 
Eszopiclone/ OR Flunitrazepam/ OR Fluoxetine/ OR Flupenthixol/ OR Fluphenazine/ OR Fluvoxamine/ 
OR Guanfacine/ OR Haloperidol/ OR Imipramine/ OR Isocarboxazid/ OR Methotrimeprazine/ OR 
Lithium/ OR Lithium Carbonate/ OR Lorazepam/ OR Loxapine/ OR Lurasidone Hydrochloride/ OR 
Methylphenidate/ OR Mianserin/ OR Midazolam/ OR Moclobemide/ OR Molindone/ OR Nitrazepam/ 
OR Nortriptyline/ OR Oxazepam/ OR Paliperidone Palmitate/ OR Paroxetine/ OR Phenelzine/ OR 
Phenobarbital/ OR Pindolol/ OR Prazepam/ OR Pregabalin/ OR Prochlorperazine/ OR Promazine/ OR 
Promethazine/ OR Propranolol/ OR Protriptyline/ OR Quetiapine Fumarate/ OR Remoxipride/ OR 
 Risperidone/ OR Selegiline/ OR Sertraline/ OR Sulpiride/ OR Temazepam/ OR Thioridazine/ OR 
Thiothixene/ OR Tranylcypromine/ OR Trazodone/ OR Triazolam/ OR Trifluoperazine/ OR 
Trimipramine/ OR Venlafaxine Hydrochloride/ OR Vigabatrin/ OR ((Adrenergic adj Beta adj2 
(Antagonist OR Block$)) OR Anti Anxiety OR Anti Convuls$ OR Anti Depress$ OR Anti Epilep$ OR Anti 
Psychotic? OR Antianxiety OR Anticonvuls$ OR Antidepress$ OR Antiepilep$ OR Antipsychotic$ OR 
Anxiolytic$ OR Benzodiazepine$ OR (Beta adj Block$) OR (Beta adj1 Adrenergic adj2 Block$) OR 
Thymoanaleptic$ OR Thymoleptic$ OR Agomelatine OR "S 20098" OR S20098 OR Thymanax OR 
Valdoxan OR "AGO 178" OR AGO178 OR Alprazolam OR Alprazolan OR "Apo Alpraz" OR ApoAlpraz OR 
Cassadan OR "D 65MT" OR D65MT OR Xanax OR Tafil OR Trankimazin OR "Novo Alprazol" OR 
NovoAlprazol OR "Nu Alpraz" OR NuAlpraz OR Ralozam OR "U-31,889" OR "U31,889" OR Alprox OR 
Esparon OR Kalma OR Amisulpride OR Sultopride OR Barnetil OR "DAN 2163" OR Solian OR "LIN 1418" 
OR Amitriptyline OR Amineurin OR Amitrip OR Amitriptylin OR Amitrol OR Tryptine OR 
ApoAmitriptyline OR Damilen OR Domical OR Laroxyl OR Endep OR Lentizol OR Novoprotect OR 
Saroten OR Sarotex OR Syneudon OR Triptafen OR Tryptizol OR Tryptanol OR Elavil OR Anapsique OR 
Amoxapine OR Desmethylloxapine OR "CL 67,772" OR "CL67,772" OR Demolox OR Asendin OR 
Defanyl OR Asendis OR Aripiprazole OR Aripiprazol OR "OPC 14597" OR Abilify OR Asenapine OR 
Saphris OR " OR G 5222" OR Atenolol OR Tenormine OR Tenormin OR "ICI 66082" OR ICI66082 OR 
Atomoxetine OR Tomoxetine OR Strattera OR "LY 139603" OR Benztropine OR Benzatropine OR 
Bensylate OR PMSBenztropine OR Cogentin OR Cogentinol OR Methylbenztropine OR ApoBenztropine 
OR Brexpiprazole OR Bromazepam OR BromaLich OR "Bromaz 1A Pharma" OR Bromazanil OR 
"Bromazep von CT" OR Durazanil OR Lexotan OR Lexotanil OR Lexatin OR Lexomil OR "Ro 5-3350" OR 
"Ro 53350" OR Anxyrex OR Bupropion OR Amfebutamone OR Zyntabac OR Quomen OR Wellbutrin OR 
Zyban OR Buspirone OR "MJ 9022 1" OR MJ90221 OR Neurosine OR Busp OR Anxut OR Buspar OR 
Bespar OR Carbamazepine OR Tegretol OR Carbazepin OR Epitol OR Finlepsin OR Neurotol OR 
Amizepine OR Cariprazine OR "RGH 188" OR Chlordiazepoxide OR Methaminodiazepoxide OR Librium 
 OR Chlozepid OR Elenium OR Chlorpromazine OR Thorazine OR Aminazine OR Largactil OR 
Chlordelazine OR Contomin OR Fenactil OR Propaphenin OR Chlorazine OR Citalopram OR Cytalopram 
OR "Lu 10 171" OR Lu10171 OR Escitalopram OR Lexapro OR Clobazam OR "HR 376" OR Onfi OR "LM 
2717" OR Frisium OR Urbanyl OR Clomipramine OR Chlomipramine OR Chlorimipramine OR Hydiphen 
OR Anafranil OR Clonazepam OR "Ro 5 4023" OR "Ro 54023" OR Antelepsin OR Rivotril OR 
Clopenthixol OR Zuclopenthixol OR Cisordinol OR Clorazepate OR Chlorazepate OR Tranxene OR 
Tranxilium OR "4306 CB" OR Clozapine OR Clozaril OR Leponex OR Desipramine OR 
Desmethylimipramine OR Demethylimipramine OR Norpramin OR Pertofrane OR Pertrofran OR 
Pertofran OR Petylyl OR Desvenlafaxine OR "O Desmethylvenlafaxine" OR "WY 45,233" OR "WY 
45,233" OR "WY45,233" OR "WY 45233" OR WY45233 OR Pristiq OR Dextroamphetamine OR 
Dexamphetamine OR Dexamfetamine OR "Dextro Amphetamine" OR "D Amphetamine" OR 
Dexedrine OR DextroStat OR Oxydess OR Diazepam OR Diazemuls OR Faustan OR Valium OR Seduxen 
OR Sibazon OR Stesolid OR Apaurin OR Relanium OR "Valproic Acid" OR Divalproex OR 
"Propylisopropylacetic Acid" OR "2 Propylpentanoic Acid" OR Convulsofin OR Depakene OR Depakine 
OR Depakote OR Vupral OR Valproate OR Ergenyl OR "Dipropyl Acetate" OR Domperidone OR 
Domperidon OR Domidon OR Gastrocure OR Motilium OR Nauzelin OR Peridys OR "R 33,812" OR 
"R33,812" OR "R 33812" OR R33812 OR Dothiepin OR Dosulepin OR Prothiaden OR Doxepin OR 
Deptran OR Desidox OR Doneurin OR Doxepia OR Espadox OR Mareen OR Prudoxin OR Quitaxon OR 
Sinequan OR Sinquan OR Zonalon OR Xepin OR Aponal OR ApoDoxepin OR Droperidol OR Inapsine OR 
Dehidrobenzperidol OR Dehydrobenzperidol OR Droleptan OR Duloxetine OR "LY 248686" OR 
LY248686 OR "LY 227942" OR LY227942 OR Cymbalta OR Estazolam OR Tasedan OR ProSom OR "D 
40TA" OR D40TA OR Nuctalon OR Eszopiclone OR Lunesta OR Estorra OR Flunitrazepam OR 
Fluridrazepam OR Flunibeta OR Flunimerck OR Fluninoc OR Rohypnol OR Rohipnol OR Narcozep OR 
"Flunizep von CT" OR "RO 5 4200" OR RO54200 OR Fluoxetine OR Fluoxetin OR "Lilly 110140" OR 
Lilly110140 OR Sarafem OR Prozac OR Flupenthixol OR Flupentixol OR Emergil OR Fluanxol OR 
 Fluphenazine OR Flufenazin OR Lyogen OR Prolixin OR Fluvoxamine OR Fluvoxadura OR Fluvoxamin 
OR Fluvoxamina OR Luvox OR Fevarin OR Floxyfral OR Dumirox OR Faverin OR Desiflu OR "DU 23000" 
OR DU23000 OR Guanfacine OR Tenex OR Lon798 OR "BS 100 141" OR BS100141 OR Estulic OR 
Haloperidol OR Haldol OR Iloperidone OR Zomaril OR Fanapt OR "HP 873" OR Imipramine OR Imizin 
OR Norchlorimipramine OR Imidobenzyle OR Tofranil OR Melipramine OR Pryleugan OR Janimine OR 
Isocarboxazid OR Lamotrigine OR Crisomet OR Lamictal OR Lamiktal OR "BW 430C" OR Labileno OR 
Methotrimeprazine OR Levomepromazine OR Levopromazine OR Levomeprazin OR Tisercin OR 
Tizercine OR Tizertsin OR Lithium OR Dilithium OR Lithane OR Lithobid OR Lithonate OR "CP-15,467 
61" OR "CP15,46761" OR Micalith OR "NSC 16895" OR NSC16895 OR Priadel OR "Quilinorm Retard" 
OR Quilinormretard OR Eskalith OR Lithotabs OR Lorazepam OR Ativan OR Temesta OR "Orfidal 
Wyeth" OR Donix OR Duralozam OR Durazolam OR Idalprem OR Laubeel OR "Lorazep von CT" OR 
"Novo Lorazem" OR NovoLorazem OR "Nu Loraz" OR NuLoraz OR Sedicepan OR Sinestron OR 
Somagerol OR Tolid OR "WY 4036" OR WY4036 OR ApoLorazepam OR Loxapine OR Cloxazepine OR 
Oxilapine OR Loxitane OR Loxipine OR Loxapinsuccinate OR "CL 71,563" OR "CL71,563" OR Lurasidone 
OR "SM 13496" OR SM13496 OR "SM-13,496" OR "SM13,496" OR Latuda OR Methylphenidate OR 
Metadate OR Equasym OR Methylin OR Concerta OR Phenidylate OR Ritalin OR Ritaline OR Tsentedrin 
OR Centedrin OR Daytrana OR Mianserin OR Tolvon OR Lerivon OR Org GB 94 OR Midazolam OR 
Dormicum OR Versed OR "Ro 21 3981" OR "Ro 213981" OR Milnacipran OR Midalcipran OR 
Levomilnacipran OR Savella OR "F 2207" OR Ixel OR Mirtazapine OR "6 Azamianserin" OR 
Esmirtazapine OR Remeron OR Remergil OR Zispin OR Norset OR Rexer OR "Org 50081" OR " OR G 
3770" OR Moclobemide OR Moclobamide OR Arima OR Aurorix OR Manerix OR Moclamine OR 
Aurorex OR Deprenorm OR Feraken OR Moclobemid OR Moclobeta OR Moclodura OR Moclonorm OR 
Rimoc OR "Ro 11 1163" OR Modafinil OR Benzhydrylsulfinylacetamide OR "CRL 40476" OR Vigil OR 
Provigil OR Sparlon OR Alertec OR Modiodal OR Molindone OR Moban OR Nefazodone OR Rulivan OR 
Serzone OR Dutonin OR Nefadar OR Menfazona OR Nitrazepam OR Nitrodiazepam OR "Dormo Puren" 
 OR Eatan OR Imadorm OR Imeson OR Mogadon OR Nitrazadon OR Nitrazep OR Novanox OR 
Radedorm OR Remnos OR Serenade OR Somnite OR Alodorm OR Dormalon OR Nortriptyline OR 
Desmethylamitriptylin OR Desitriptyline OR Aventyl OR Paxtibi OR Allegron OR Norfenazin OR 
Pamelor OR Nortrilen OR Olanzapine OR Zolafren OR "LY 170052" OR Zyprexa OR "LY 170053" OR 
Oxazepam OR Serax OR Tazepam OR Adumbran OR Oxcarbazepine OR Timox OR Trileptal OR "GP 
47680" OR Paliperidone OR "9 OH Risperidone" OR "9 Hydroxy Risperidone" OR "9 
Hydroxyrisperidone" OR Invega OR "R 76477" OR R76477 OR Paroxetine OR "BRL 29060" OR 
BRL29060 OR "FG 7051" OR FG7051 OR Seroxat OR Paxil OR Aropax OR Periciazine OR Propericiazine 
OR Pericyazine OR Neuleptil OR Neuleptyl OR Aolept OR Phenelzine OR "Beta Phenylethylhydrazine" 
OR "2 Phenethylhydrazine" OR Fenelzin OR Phenethylhydrazine OR Nardelzine OR Nardil OR 
Phenobarbital OR Phenobarbitone OR "Phenylethylbarbituric Acid" OR Phenemal OR Phenylbarbital 
OR Hysteps OR Luminal OR Gardenal OR Pindolol OR Prindolol OR Visken OR "LB 46" OR LB46 OR 
Prazepam OR Lysanxia OR Reapam OR Centrax OR Demetrin OR Pregabalin OR "3 Isobutyl GABA" OR 
Lyrica OR "CI 1008" OR CI1008 OR Prochlorperazine OR Compazine OR Promazine OR Sparine OR 
Sinophenin OR Protactyl OR Promethazine OR Prometazin OR Proazamine OR Rumergan OR Diprazin 
OR Phenergan OR Phenargan OR Phensedyl OR Pipolfen OR Pipolphen OR Promet OR Prothazin OR 
Pyrethia OR Remsed OR Atosil OR Diphergan OR Propranolol OR Propanolol OR Inderal OR Avlocardyl 
OR "AY 20694" OR AY20694 OR Rexigen OR Dexpropranolol OR Dociton OR Obsidan OR Obzidan OR 
Anaprilin OR Anapriline OR Betadren OR Protriptyline OR Vivactil OR Quetiapine OR "ICI 204,636" OR 
"ICI 204636" OR ICI204636 OR Seroquel OR Reboxetine OR Vestra OR Remoxipride OR "FLA 731" OR 
FLA731 OR Risperidone OR Risperdal OR Risperidal OR "R 64,766" OR "R64,766" OR "R 64766" OR 
R64766 OR Selegiline OR Selegyline OR "L Deprenyl" OR "E 250" OR E250 OR Eldepryl OR Emsam OR 
Zelapar OR Deprenil OR Deprenalin OR Yumex OR Jumex OR Humex OR Deprenyl OR Sertindole OR 
Serlect OR "Lu 23 174" OR Serdolect OR Sertraline OR Zoloft OR Altruline OR Lustral OR Aremis OR 
Besitran OR Sealdin OR Gladem OR Sulpiride OR Sulperide OR Arminol OR Deponerton OR Meresa OR 
 Desisulpid OR Digton OR Dogmatil OR Dolmatil OR Eglonyl OR Ekilid OR Guastil OR Lebopride OR 
Neogama OR Pontiride OR Psicocen OR Sulp OR Sulpitil OR Sulpivert OR Sulpor OR Synedil OR Tepavil 
OR Aiglonyl OR Temazepam OR Hydroxydiazepam OR Methyloxazepam OR Signopam OR Tenox OR 
"WY 3917" OR WY3917 OR Dasuen OR Euhypnos OR Levanxol OR "Norkotral Tema" OR Normison OR 
Nocturne OR Temtabs OR Normitab OR Nortem OR Planum OR "Pronervon T" OR Remestan OR 
Restoril OR "Ro 5 5345" OR Ro55345 OR "SaH 47 603" OR "SaH 47603" OR Temaze OR "Temazep von 
CT" OR Thioridazine OR ApoThioridazine OR Meleril OR Melleril OR Melleryl OR Mellaril OR 
Melleretten OR Melzine OR Thiozine OR Sonapax OR Thioridazineneurazpharm OR Aldazine OR Rideril 
OR Thiothixene OR Tiotixene OR Navane OR Topiramate OR USL255 OR "McN 4853" OR Topamax OR 
Epitomax OR Tranylcypromine OR "Trans 2 Phenylcyclopropylamine" OR Jatrosom OR Transamine OR 
Parnate OR Trazodone OR Tradozone OR "AF 1161" OR AF1161 OR Deprax OR Desyrel OR Molipaxin 
OR Trittico OR Thombran OR "Trazodon Hexal" OR "Trazodon Neuraxpharm" OR Trazon OR Triazolam 
OR "U 33,030" OR "U33,030" OR Halcion OR Trilam OR "Apo Triazo" OR Trifluoperazine OR 
Trifluoroperazine OR Trifluperazine OR Eskazine OR Flupazine OR Terfluzine OR Triftazin OR Stelazine 
OR Trimipramine OR Trimeprimine OR Herphonal OR Trimineurin OR NovoTripramine OR Rhotrimine 
OR Stangyl OR Surmontil OR Trimidura OR Trimineurin OR Trimipramin OR "Apo Trimip" OR 
ApoTrimip OR Eldoral OR Venlafaxine OR "Wy 45030" OR Wy45030 OR "Wy 45,030" OR "Wy45,030" 
OR Effexor OR Trevilor OR Vandral OR Efexor OR Dobupal OR Vigabatrin OR "Gamma Vinyl GABA" OR 
"Gamma Vinyl Gamma Aminobutyric Acid" OR Sabril OR Sabrilex OR Vortioxetine OR Brintellix OR "Lu 
AA21004" OR LuAA21004 OR Zaleplon OR "SKP 1041" OR Sonata OR Zelepion OR Starnoc OR "CL 
284,846" OR "CL284,846" OR "CL 284846" OR "L 846" OR Ziprasidone OR Ziprazidone OR "CP 88,059" 
OR "CP 88059" OR Zolpidem OR Amsic OR Bikalm OR Dalparan OR "SL 80.0750" OR "SL 800750 23 N" 
OR Stilnoct OR Stilnox OR Zodormdura OR Zoldem OR Zolirin OR "Zolpi Lich" OR Zolpinox OR Zolpimist 
OR Ambien OR Zopiclone OR Zop OR Zopicalma OR Zopiclodura OR Zopiclon OR Zopitan OR Zorclone 
OR Imovane OR Ximovan OR Zimovane OR Limovan OR Optidorm OR Rhovane OR "RP 27 267" OR 
 Siaten OR Somnosan OR Zileze OR Zimoclone OR "Zopi Puren" OR Zopicalm OR Zotepine OR Zoleptil 
OR Nipolept OR Zuclopenthixol OR Zuclopentixol OR Clopixol OR Zuclopenthixole OR Acuphase).ti,ab. 
3. (1 AND 2) NOT (Animals NOT (Humans NOT Animals)).sh. 
Limit 3 to English 
APPENDIX 2 
Joanna Briggs Institute Critical appraisal checklists  
Critical appraisal checklist for case control studies 
1. Were the groups comparable other than presence of disease in cases or absence of disease in 
controls? 
2. Were cases and controls matched appropriately? 
3. Were the same criteria used for identification of cases and controls? 
4. Was exposure measured in a standard, valid and reliable way? 
5. Was exposure measured in the same way for cases and controls? 
6. Were confounding factors identified? 
7. Were strategies to deal with confounding factors stated? 
8. Were outcomes assessed in a standard, valid and reliable way for cases and controls? 
9. Was the exposure period of interest long enough to be meaningful? 
10. Was appropriate statistical analysis used? 
 
 Critical appraisal checklist for cohort studies 
1. Were the two groups similar and recruited from the same population? 
2. Were the exposures measured similarly to assign people to both exposed and unexposed groups? 
3. Was the exposure measured in a valid and reliable way? 
 4. Were confounding factors identified? 
5. Were strategies to deal with confounding factors stated? 
6. Were the groups/participants free of the outcome at the start of the study (or moment of 
exposure)? 
7. Were the outcomes measured in a valid and reliable way? 
8. Was the follow up time reported and sufficient to be long enough for outcomes to occur? 
9. Was follow up complete, and if not, were the reasons to loss to follow up described and 
explored? 
10. Were strategies to address incomplete follow up utilized? 
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